Wednesday - January 8, 2025
BRISBANE, Calif. / Dec 18, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco.
CareDx’s management is scheduled to present on Tuesday, January 14, 2025, at 4:30 p.m. Pacific Time (7:30 p.m Eastern Time). To listen to the webcast, please visit the Events & Presentations section of CareDx’s Investor Relations website at: investors.caredx.com.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
Last Trade: | US$22.69 |
Daily Change: | -0.03 -0.13 |
Daily Volume: | 22,260 |
Market Cap: | US$1.220B |
December 11, 2024 November 04, 2024 October 23, 2024 October 21, 2024 October 15, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load